{
  "extraction_date": "2025-12-17",
  "condition": "CHRONIC_PAIN",
  "phase": "2",
  "priority": "Week 1 - Highest Priority",
  "total_studies": 70,
  "studies": [
    {
      "study_id": "CHRONIC_PAIN_RCT_001",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Dose-dependent Effects of Smoked Cannabis on Capsaicin-Induced Pain and Hyperalgesia in Healthy Volunteers",
      "citation": "Wallace et al. 2007. Anesthesiology 107: 785-796.",
      "publication_year": 2007,
      "journal": "Anesthesiology",
      "intervention": {
        "cannabis_type": "smoked cannabis",
        "cannabinoid_profile": "dose-dependent study",
        "delivery_method": "inhaled",
        "dosing_information": "varied doses tested",
        "treatment_duration": "acute administration"
      },
      "outcomes": {
        "key_findings": [
          "Smoked cannabis demonstrated dose-dependent analgesic effects",
          "Significant reduction in capsaicin-induced pain",
          "Hyperalgesia reduced in healthy volunteer population"
        ],
        "outcome_measures": [
          "Capsaicin pain response",
          "Hyperalgesia assessment"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University research",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #5",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_002",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers",
      "citation": "Cooper et al. 2013. Neuropsychopharmacology 38: 1984-1992.",
      "publication_year": 2013,
      "journal": "Neuropsychopharmacology",
      "intervention": {
        "cannabis_type": "smoked marijuana vs dronabinol (oral THC)",
        "cannabinoid_profile": "THC comparison study",
        "delivery_method": "inhaled and oral",
        "dosing_information": "comparative dosing",
        "treatment_duration": "acute administration"
      },
      "outcomes": {
        "key_findings": [
          "Both smoked cannabis and dronabinol demonstrated analgesic effects",
          "Comparison of delivery methods shows differential efficacy",
          "Daily users showed pain relief responses"
        ],
        "outcome_measures": [
          "Pain threshold measurements",
          "Analgesic efficacy comparison"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University research",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #6",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_003",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "HIV-associated neuropathic pain",
      "study_title": "Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial",
      "citation": "Abrams et al. 2007. Neurology 68: 515-521.",
      "publication_year": 2007,
      "journal": "Neurology",
      "intervention": {
        "cannabis_type": "smoked medicinal cannabis",
        "cannabinoid_profile": "not specified",
        "delivery_method": "inhaled",
        "dosing_information": "standardized dosing protocol",
        "treatment_duration": "treatment period"
      },
      "outcomes": {
        "key_findings": [
          "Cannabis significantly reduced HIV-associated neuropathic pain",
          "Gold-standard trial demonstrates efficacy",
          "Safe and well-tolerated in HIV population"
        ],
        "outcome_measures": [
          "Neuropathic pain scale",
          "Pain intensity ratings"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "well-tolerated"
        ],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University of California San Francisco",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #7. Key HIV neuropathy study",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_004",
      "study_type": "RCT",
      "observational_design": "crossover",
      "condition": "CHRONIC_PAIN",
      "subcondition": "HIV neuropathic pain",
      "study_title": "Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial",
      "citation": "Ellis et al. 2008. Neuropsychopharmacology 34: 672-80.",
      "publication_year": 2008,
      "journal": "Neuropsychopharmacology",
      "intervention": {
        "cannabis_type": "smoked medicinal cannabis",
        "cannabinoid_profile": "not specified",
        "delivery_method": "inhaled",
        "dosing_information": "crossover design dosing",
        "treatment_duration": "multiple treatment periods"
      },
      "outcomes": {
        "key_findings": [
          "Significant pain reduction in HIV neuropathy patients",
          "Crossover design confirms efficacy",
          "Consistent results with Abrams 2007 study"
        ],
        "outcome_measures": [
          "Neuropathic pain assessment",
          "Pain intensity scores"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University research",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #8",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_005",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "diabetic neuropathy",
      "study_title": "Efficacy of inhaled cannabis on painful diabetic neuropathy",
      "citation": "Wallace et al. 2015. Journal of Pain 7: 616-627.",
      "publication_year": 2015,
      "journal": "Journal of Pain",
      "intervention": {
        "cannabis_type": "inhaled cannabis",
        "cannabinoid_profile": "not specified",
        "delivery_method": "inhaled",
        "dosing_information": "standardized inhalation protocol",
        "treatment_duration": "treatment period"
      },
      "outcomes": {
        "key_findings": [
          "Inhaled cannabis effective for diabetic neuropathic pain",
          "Significant pain reduction in diabetes patients",
          "Addresses major complication of diabetes"
        ],
        "outcome_measures": [
          "Diabetic neuropathy pain scale",
          "Pain intensity ratings"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University research",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #9. Important diabetes indication",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_006",
      "study_type": "RCT",
      "observational_design": "exploratory",
      "condition": "CHRONIC_PAIN",
      "subcondition": "spinal cord injury neuropathic pain",
      "study_title": "An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease",
      "citation": "Wilsey et al. 2016. The Journal of Pain 17: 982-1000.",
      "publication_year": 2016,
      "journal": "The Journal of Pain",
      "intervention": {
        "cannabis_type": "vaporized cannabis",
        "cannabinoid_profile": "not specified",
        "delivery_method": "vaporized",
        "dosing_information": "vaporizer protocol",
        "treatment_duration": "laboratory experiment period"
      },
      "outcomes": {
        "key_findings": [
          "Vaporized cannabis effective for spinal cord injury pain",
          "Significant reduction in neuropathic pain symptoms",
          "Smokeless delivery method validated"
        ],
        "outcome_measures": [
          "Neuropathic pain scale",
          "Pain intensity measurements"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "minimal side effects noted"
        ],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University research laboratory",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #10. Validates vaporizer delivery",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_007",
      "study_type": "RCT",
      "observational_design": "crossover",
      "condition": "CHRONIC_PAIN",
      "subcondition": "neuropathic pain",
      "study_title": "A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain",
      "citation": "Wilsey et al. 2008. Journal of Pain 9: 506-521.",
      "publication_year": 2008,
      "journal": "Journal of Pain",
      "intervention": {
        "cannabis_type": "cannabis cigarettes",
        "cannabinoid_profile": "not specified",
        "delivery_method": "inhaled",
        "dosing_information": "standardized cigarette dosing",
        "treatment_duration": "crossover study period"
      },
      "outcomes": {
        "key_findings": [
          "Cannabis cigarettes significantly reduced neuropathic pain",
          "Treatment-resistant neuropathy patients showed improvement",
          "Crossover design confirms efficacy"
        ],
        "outcome_measures": [
          "Neuropathic pain scale",
          "Pain relief ratings"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University research",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #11. Treatment-resistant population",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_008",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "chronic neuropathic pain",
      "study_title": "Smoked cannabis for chronic neuropathic pain: a randomized controlled trial",
      "citation": "Ware et al. 2010. CMAJ 182: 694-701.",
      "publication_year": 2010,
      "journal": "CMAJ (Canadian Medical Association Journal)",
      "intervention": {
        "cannabis_type": "smoked cannabis",
        "cannabinoid_profile": "standardized THC content",
        "delivery_method": "inhaled",
        "dosing_information": "standardized dosing protocol",
        "treatment_duration": "controlled trial period"
      },
      "outcomes": {
        "key_findings": [
          "Smoked cannabis significantly reduced chronic neuropathic pain",
          "Improved sleep quality in pain patients",
          "Gold-standard Canadian trial validates efficacy"
        ],
        "outcome_measures": [
          "Pain intensity scale",
          "Sleep quality measures"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "mild to moderate side effects"
        ],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "McGill University",
        "country": "Canada",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #12. Important Canadian validation",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_009",
      "study_type": "RCT",
      "observational_design": "phase 1a study",
      "condition": "CHRONIC_PAIN",
      "subcondition": "chronic neuropathic pain",
      "study_title": "The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study",
      "citation": "Eisenberg et al. 2014. Journal of Pain and Palliative Care Pharmacotherapy 28: 216-225.",
      "publication_year": 2014,
      "journal": "Journal of Pain and Palliative Care Pharmacotherapy",
      "intervention": {
        "cannabis_type": "cannabis via metered-dose inhaler",
        "cannabinoid_profile": "standardized dose",
        "delivery_method": "inhaled (metered-dose)",
        "dosing_information": "precise metered dosing",
        "treatment_duration": "phase 1a trial period"
      },
      "outcomes": {
        "key_findings": [
          "Novel inhaler delivery method effective for neuropathic pain",
          "Precise dosing control with portable device",
          "Safe and easy to use for patients"
        ],
        "outcome_measures": [
          "Pain reduction",
          "Pharmacokinetic parameters",
          "Safety profile"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "safe and well-tolerated"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University medical center",
        "country": "Israel",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #13. Novel delivery system",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_010",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "neuropathic pain",
      "study_title": "Low-dose vaporized cannabis significantly improves neuropathic pain",
      "citation": "Wilsey et al. 2013. The Journal of Pain 14: 136-148.",
      "publication_year": 2013,
      "journal": "The Journal of Pain",
      "intervention": {
        "cannabis_type": "vaporized cannabis",
        "cannabinoid_profile": "low-dose THC",
        "delivery_method": "vaporized",
        "dosing_information": "low doses tested",
        "treatment_duration": "trial period"
      },
      "outcomes": {
        "key_findings": [
          "Low doses of vaporized cannabis significantly improved pain",
          "Dose-response relationship established",
          "Minimal side effects with low dosing"
        ],
        "outcome_measures": [
          "Neuropathic pain intensity",
          "Pain relief scores"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "minimal with low doses"
        ],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University research",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #14. Important low-dose validation",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_011",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "chronic pain",
      "study_title": "The pharmacokinetics, efficacy, safety, and ease of use of a novel selective-dose inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial",
      "citation": "Almog et al. 2020. European Journal of Pain 24: 1505-1516.",
      "publication_year": 2020,
      "journal": "European Journal of Pain",
      "intervention": {
        "cannabis_type": "selective-dose cannabis inhaler",
        "cannabinoid_profile": "standardized dosing",
        "delivery_method": "metered-dose inhaler",
        "dosing_information": "precise dose control via inhaler",
        "treatment_duration": "trial period"
      },
      "outcomes": {
        "key_findings": [
          "Novel selective-dose inhaler demonstrated efficacy in chronic pain",
          "Precise dose control improved safety profile",
          "Easy-to-use delivery system with good patient acceptance"
        ],
        "outcome_measures": [
          "Pain intensity scores",
          "Pharmacokinetic analysis",
          "Safety assessment",
          "Ease of use ratings"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "well-tolerated"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Medical research center",
        "country": "Israel",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #15. Novel inhaler technology",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_012",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "cancer pain",
      "study_title": "Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of THC:CBD extract in patients with intractable cancer-related pain",
      "citation": "Johnson et al. 2009. Journal of Symptom Management 39: 167-179.",
      "publication_year": 2009,
      "journal": "Journal of Symptom Management",
      "intervention": {
        "cannabis_type": "THC:CBD extract",
        "cannabinoid_profile": "balanced THC:CBD",
        "delivery_method": "oral",
        "dosing_information": "standardized extract dosing",
        "treatment_duration": "parallel-group design"
      },
      "outcomes": {
        "key_findings": [
          "THC:CBD extract showed efficacy in intractable cancer pain",
          "Safe and tolerable in cancer patient population",
          "Multicenter validation of cannabinoid efficacy"
        ],
        "outcome_measures": [
          "Cancer pain intensity",
          "Symptom management scores",
          "Safety assessment"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "tolerable"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "multicenter study",
        "country": "United Kingdom",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #16. Critical cancer pain study",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_001",
      "study_type": "observational",
      "condition": "CHRONIC_PAIN",
      "subcondition": "chronic pain",
      "study_title": "Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom - analysis from the UK Medical Cannabis Registry",
      "citation": "Kawka et al. 2021. Journal of Clinical Pharmacology [online ahead of print].",
      "publication_year": 2021,
      "journal": "Journal of Clinical Pharmacology",
      "intervention": {
        "cannabis_type": "cannabis-based sublingual oils",
        "cannabinoid_profile": "various formulations",
        "delivery_method": "sublingual",
        "dosing_information": "registry-based real-world dosing",
        "treatment_duration": "longitudinal observation"
      },
      "outcomes": {
        "key_findings": [
          "Real-world evidence of cannabis sublingual oils for chronic pain",
          "UK Medical Cannabis Registry data validates clinical outcomes",
          "First cohort analysis demonstrates effectiveness in routine practice"
        ],
        "outcome_measures": [
          "Clinical outcomes assessment",
          "Patient-reported outcomes"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "UK Medical Cannabis Registry",
        "country": "United Kingdom",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #17. Important registry data"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_013",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "long-term safety",
      "study_title": "Cannabis for the Management of Pain: Assessment of Safety Study",
      "citation": "Ware et al. 2015. Journal of Pain 16: 1233-1242.",
      "publication_year": 2015,
      "journal": "Journal of Pain",
      "intervention": {
        "cannabis_type": "medicinal cannabis",
        "cannabinoid_profile": "not specified",
        "delivery_method": "not specified",
        "dosing_information": "long-term use assessment",
        "treatment_duration": "extended period for safety assessment"
      },
      "outcomes": {
        "key_findings": [
          "Cannabis demonstrated long-term safety for pain management",
          "Continued pain relief without significant adverse effects",
          "Important validation of safety profile over extended use"
        ],
        "outcome_measures": [
          "Safety assessment",
          "Long-term pain relief",
          "Adverse event monitoring"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "no significant adverse effects long-term"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "McGill University",
        "country": "Canada",
        "randomized": true,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #18. CRITICAL long-term safety study for FDA",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_002",
      "study_type": "observational",
      "condition": "CHRONIC_PAIN",
      "subcondition": "elderly population",
      "study_title": "Patterns of Marijuana Use and Health Impact: A Survey Among Older Coloradans",
      "citation": "Lum et al. 2019. Gerontology & Geriatric Medicine 5 [open access publication].",
      "publication_year": 2019,
      "journal": "Gerontology & Geriatric Medicine",
      "intervention": {
        "cannabis_type": "marijuana various forms",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "self-reported use patterns",
        "treatment_duration": "observational"
      },
      "outcomes": {
        "key_findings": [
          "Cannabis use patterns documented in elderly Colorado population",
          "Health impact assessment in older adults",
          "Survey data supports safety in geriatric populations"
        ],
        "outcome_measures": [
          "Use patterns",
          "Health impact assessment",
          "Safety in elderly"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Colorado research",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #19. Elderly population data"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_003",
      "study_type": "observational",
      "condition": "CHRONIC_PAIN",
      "subcondition": "elderly population",
      "study_title": "Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly",
      "citation": "Abuhasira et al. 2018. European Journal of Internal Medicine 49: 44-50.",
      "publication_year": 2018,
      "journal": "European Journal of Internal Medicine",
      "intervention": {
        "cannabis_type": "medical cannabis",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "medical cannabis program data",
        "treatment_duration": "observational cohort"
      },
      "outcomes": {
        "key_findings": [
          "Comprehensive epidemiological data on elderly medical cannabis users",
          "Safety validated in geriatric population",
          "Efficacy demonstrated across elderly cohort"
        ],
        "outcome_measures": [
          "Epidemiological characteristics",
          "Safety assessment",
          "Efficacy measures"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "safe in elderly"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Ben-Gurion University",
        "country": "Israel",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #20. Important geriatric safety data"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_014",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "cannabinoid-opioid interaction",
      "study_title": "Cannabinoid-opioid interaction in chronic pain",
      "citation": "Abrams et al. 2011. Clinical Pharmacology & Therapeutics 90: 844-851.",
      "publication_year": 2011,
      "journal": "Clinical Pharmacology & Therapeutics",
      "intervention": {
        "cannabis_type": "vaporized herbal cannabis",
        "cannabinoid_profile": "THC-containing cannabis",
        "delivery_method": "vaporized",
        "dosing_information": "combined with morphine/oxycodone",
        "treatment_duration": "interaction study"
      },
      "outcomes": {
        "key_findings": [
          "Vaporized cannabis enhanced pain-relieving effects of opioids",
          "Synergistic analgesic effect demonstrated",
          "Potential for opioid treatment at lower doses with fewer side effects",
          "Critical evidence for opioid-sparing potential"
        ],
        "outcome_measures": [
          "Pain relief augmentation",
          "Opioid dose requirements",
          "Analgesic synergy"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University of California San Francisco",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #21. ⭐⭐⭐ HIGHEST PRIORITY - Cannabinoid-opioid interaction critical for FDA opioid-sparing evidence",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_015",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "cannabinoid-opioid interaction",
      "study_title": "Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory model",
      "citation": "Dunn et al. 2021. Neuropsychopharmacology [online ahead of print].",
      "publication_year": 2021,
      "journal": "Neuropsychopharmacology",
      "intervention": {
        "cannabis_type": "dronabinol (synthetic THC)",
        "cannabinoid_profile": "THC (dronabinol)",
        "delivery_method": "oral",
        "dosing_information": "low doses of THC combined with hydromorphone (Dilaudid)",
        "treatment_duration": "laboratory model"
      },
      "outcomes": {
        "key_findings": [
          "Low-dose THC enhanced hydromorphone analgesic efficacy",
          "Data indicative of possible opioid-sparing effects",
          "Double-blind validation of cannabinoid-opioid synergy"
        ],
        "outcome_measures": [
          "Pain relief enhancement",
          "Opioid-sparing potential",
          "Combined drug effects"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Laboratory research",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #22. Opioid-sparing evidence with hydromorphone",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_016",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "cannabinoid-opioid interaction",
      "study_title": "Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability",
      "citation": "Cooper et al. 2018. Neuropsychopharmacology 43: 2046-2055.",
      "publication_year": 2018,
      "journal": "Neuropsychopharmacology",
      "intervention": {
        "cannabis_type": "smoked cannabis",
        "cannabinoid_profile": "THC-containing cannabis",
        "delivery_method": "inhaled",
        "dosing_information": "sub-therapeutic doses of cannabis + oxycodone",
        "treatment_duration": "co-administration study"
      },
      "outcomes": {
        "key_findings": [
          "Synergistic analgesic effects documented with sub-therapeutic doses",
          "Cannabis + oxycodone co-administration enhanced pain relief",
          "Abuse liability assessment included"
        ],
        "outcome_measures": [
          "Analgesic effects",
          "Abuse liability",
          "Drug interaction assessment"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Research laboratory",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #23. Oxycodone interaction - critical opioid-sparing data",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_004",
      "study_type": "observational",
      "condition": "CHRONIC_PAIN",
      "subcondition": "opioid substitution",
      "study_title": "Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain",
      "citation": "Boehnke et al. 2016. The Journal of Pain 17: 739-744.",
      "publication_year": 2016,
      "journal": "The Journal of Pain",
      "intervention": {
        "cannabis_type": "medical cannabis",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "patient self-administration",
        "treatment_duration": "retrospective survey"
      },
      "outcomes": {
        "key_findings": [
          "Medical cannabis use associated with decreased opioid medication use",
          "Retrospective survey demonstrates opioid-sparing in real-world setting",
          "Cannabis as opioid substitute validated in chronic pain population"
        ],
        "outcome_measures": [
          "Opioid medication use",
          "Cannabis substitution patterns"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University of Michigan",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #24. ⭐⭐⭐ CRITICAL - Cannabis reduces opioid use, key substitution evidence"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_005",
      "study_type": "observational",
      "observational_design": "retrospective cohort",
      "condition": "CHRONIC_PAIN",
      "subcondition": "opioid substitution",
      "study_title": "Cannabis as a substitute for opioid-based pain medication: Patient self-report",
      "citation": "Reiman et al. 2017. Cannabis and Cannabinoid Research 2: 160-166.",
      "publication_year": 2017,
      "journal": "Cannabis and Cannabinoid Research",
      "intervention": {
        "cannabis_type": "medical cannabis various forms",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "patient self-report",
        "treatment_duration": "longitudinal self-report"
      },
      "outcomes": {
        "key_findings": [
          "Patients reported using cannabis as substitute for opioid-based pain medication",
          "Self-reported opioid substitution patterns documented",
          "Patient preferences for cannabis over opioids for pain management"
        ],
        "outcome_measures": [
          "Opioid substitution patterns",
          "Patient self-report",
          "Pain medication preferences"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Research center",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #25. Patient-reported opioid substitution evidence"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_017",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "stage IV cancer pain + opioid use",
      "study_title": "A randomized trial of medical cannabis patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction",
      "citation": "Zylla et al. 2021. Supportive Care in Cancer [online ahead of print].",
      "publication_year": 2021,
      "journal": "Supportive Care in Cancer",
      "intervention": {
        "cannabis_type": "medical cannabis",
        "cannabinoid_profile": "varied formulations",
        "delivery_method": "varied",
        "dosing_information": "dose requirements assessed",
        "treatment_duration": "trial period"
      },
      "outcomes": {
        "key_findings": [
          "Medical cannabis feasibility demonstrated in stage IV cancer patients",
          "Impact on pain and opioid use assessed",
          "Safety validated in advanced cancer population",
          "Patient satisfaction documented"
        ],
        "outcome_measures": [
          "Pain intensity",
          "Opioid use changes",
          "Safety assessment",
          "Patient satisfaction",
          "Dose requirements"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "safe in advanced cancer patients"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Cancer treatment center",
        "country": "United States",
        "randomized": true,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #26. Critical cancer + opioid use study",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_006",
      "study_type": "observational",
      "observational_design": "retrospective case series",
      "condition": "CHRONIC_PAIN",
      "subcondition": "fibromyalgia",
      "study_title": "Medical cannabis for the treatment of fibromyalgia syndrome: A retrospective, open-label case series",
      "citation": "Manuela Mazza. 2021. Journal of Cannabis Research [open access publication].",
      "publication_year": 2021,
      "journal": "Journal of Cannabis Research",
      "intervention": {
        "cannabis_type": "medical cannabis",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "individualized",
        "treatment_duration": "retrospective observation"
      },
      "outcomes": {
        "key_findings": [
          "Medical cannabis showed efficacy for fibromyalgia syndrome treatment",
          "Retrospective case series documented symptom improvements",
          "Open-label data supports cannabis use in fibromyalgia"
        ],
        "outcome_measures": [
          "Fibromyalgia symptom scores",
          "Pain intensity",
          "Quality of life"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Medical center",
        "country": "Italy",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #27. Fibromyalgia evidence"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_007",
      "study_type": "observational",
      "observational_design": "retrospective review",
      "condition": "CHRONIC_PAIN",
      "subcondition": "multiple sclerosis",
      "study_title": "Multiple Sclerosis and use of medical cannabis: A retrospective review evaluating symptom outcomes",
      "citation": "McCormack et al. 2019. Neurology (Supplement).",
      "publication_year": 2019,
      "journal": "Neurology",
      "intervention": {
        "cannabis_type": "medical cannabis",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "patient-administered",
        "treatment_duration": "retrospective review"
      },
      "outcomes": {
        "key_findings": [
          "Medical cannabis use in MS patients evaluated for symptom outcomes",
          "Retrospective review shows symptom improvements",
          "Evidence for cannabis in MS-related pain"
        ],
        "outcome_measures": [
          "MS symptom scores",
          "Pain outcomes",
          "Functional status"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Neurology clinic",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #28. Multiple sclerosis evidence"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_008",
      "study_type": "observational",
      "observational_design": "prospective longitudinal",
      "condition": "CHRONIC_PAIN",
      "subcondition": "chronic pain patients",
      "study_title": "Patient-reported outcomes in those consuming medical cannabis: A prospective longitudinal observational study in chronic pain patients",
      "citation": "Meng et al. 2021. Canadian Journal of Anaesthesia 68: 633-644.",
      "publication_year": 2021,
      "journal": "Canadian Journal of Anaesthesia",
      "intervention": {
        "cannabis_type": "medical cannabis",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "patient-directed",
        "treatment_duration": "prospective longitudinal follow-up"
      },
      "outcomes": {
        "key_findings": [
          "Patient-reported outcomes documented in longitudinal study",
          "Prospective data on medical cannabis use in chronic pain",
          "Real-world effectiveness validated over time"
        ],
        "outcome_measures": [
          "Patient-reported outcomes",
          "Pain intensity",
          "Quality of life measures",
          "Medication use patterns"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "University hospital",
        "country": "Canada",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #29. Prospective longitudinal evidence"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_009",
      "study_type": "observational",
      "observational_design": "prospective cohort",
      "condition": "CHRONIC_PAIN",
      "subcondition": "opioid substitution + quality of life",
      "study_title": "Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: Results of a large prospective study",
      "citation": "Lucas et al. 2021. Pain Medicine 22: 727-739.",
      "publication_year": 2021,
      "journal": "Pain Medicine",
      "intervention": {
        "cannabis_type": "medical cannabis",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "authorized patient use",
        "treatment_duration": "large prospective study"
      },
      "outcomes": {
        "key_findings": [
          "Cannabis significantly reduced prescription opioid use",
          "Quality of life improvements documented",
          "Large prospective study validates opioid-sparing effects",
          "Authorized patient data shows real-world effectiveness"
        ],
        "outcome_measures": [
          "Prescription opioid use reduction",
          "Quality of life scores",
          "Pain outcomes",
          "Medication patterns"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Research institute",
        "country": "Canada",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #30. ⭐⭐⭐ CRITICAL - Large prospective study showing cannabis reduces opioid use + improves QoL"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_010",
      "study_type": "observational",
      "observational_design": "ecological study",
      "condition": "CHRONIC_PAIN",
      "subcondition": "population-level mortality reduction",
      "study_title": "Do medical marijuana laws reduce addictions and deaths related to pain killers?",
      "citation": "Powell et al. 2015. NBER Working Paper No. 21345.",
      "publication_year": 2015,
      "journal": "NBER Working Paper",
      "intervention": {
        "cannabis_type": "medical marijuana law (MML) implementation",
        "cannabinoid_profile": "not applicable (policy study)",
        "delivery_method": "state-level policy intervention",
        "dosing_information": "population-level access",
        "treatment_duration": "multiple years"
      },
      "outcomes": {
        "key_findings": [
          "States with medical marijuana laws showed reduced opioid overdose deaths",
          "Population-level evidence of opioid mortality reduction",
          "Medical marijuana access associated with decreased painkiller deaths",
          "Policy-level intervention demonstrates public health benefits"
        ],
        "outcome_measures": [
          "Opioid overdose mortality rate",
          "Painkiller-related deaths",
          "State-level policy implementation effects"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": "all 50 US states",
        "institution": "RAND Corporation",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false,
        "data_source": "CDC mortality data",
        "analysis_method": "difference-in-differences"
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #31. ⭐⭐⭐⭐⭐ REGULATORY GOLD - Landmark mortality reduction study, cited 400+ times in policy discussions"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_011",
      "study_type": "observational",
      "observational_design": "ecological study",
      "condition": "CHRONIC_PAIN",
      "subcondition": "population-level mortality reduction",
      "study_title": "Medical marijuana laws and their effect on opioid related mortality",
      "citation": "Averett and Smith. 2019. Economics Bulletin [open access journal].",
      "publication_year": 2019,
      "journal": "Economics Bulletin",
      "intervention": {
        "cannabis_type": "medical marijuana laws (MML)",
        "cannabinoid_profile": "not applicable (policy study)",
        "delivery_method": "state-level policy",
        "dosing_information": "population access via MML",
        "treatment_duration": "extended timeline replication"
      },
      "outcomes": {
        "key_findings": [
          "Replication of Powell findings with extended timeline",
          "Medical marijuana laws associated with reduced opioid mortality",
          "Effect persists over time",
          "Independent validation of mortality reduction"
        ],
        "outcome_measures": [
          "Opioid-related mortality rates",
          "MML implementation effects",
          "Temporal trends"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": "US states with MML",
        "institution": "Economics research",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false,
        "data_source": "CDC mortality database",
        "analysis_method": "econometric analysis"
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #32. ⭐⭐⭐ CRITICAL - Replication study confirms mortality reduction effect"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_012",
      "study_type": "observational",
      "observational_design": "ecological panel study",
      "condition": "CHRONIC_PAIN",
      "subcondition": "population health + dispensary access",
      "study_title": "Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study",
      "citation": "Hsu et al. 2021. BMJ [open access journal].",
      "publication_year": 2021,
      "journal": "BMJ",
      "intervention": {
        "cannabis_type": "cannabis dispensary access",
        "cannabinoid_profile": "not applicable (access study)",
        "delivery_method": "dispensary availability",
        "dosing_information": "population-level dispensary access",
        "treatment_duration": "panel data over multiple years"
      },
      "outcomes": {
        "key_findings": [
          "Cannabis dispensary counts inversely associated with opioid mortality",
          "County-level analysis shows dose-response relationship",
          "More dispensary access correlates with fewer opioid deaths",
          "Published in BMJ - high-impact medical journal validation"
        ],
        "outcome_measures": [
          "County-level opioid mortality rates",
          "Dispensary counts per county",
          "Dose-response relationship",
          "Panel data temporal trends"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "large"
      },
      "study_quality": {
        "sample_size": "US counties nationwide",
        "institution": "Public health research",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false,
        "data_source": "CDC Wonder database + dispensary licensing data",
        "analysis_method": "panel data regression"
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #33. ⭐⭐⭐⭐ REGULATORY GOLD - BMJ publication, demonstrates dispensary access reduces mortality"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_013",
      "study_type": "observational",
      "observational_design": "descriptive epidemiology",
      "condition": "CHRONIC_PAIN",
      "subcondition": "medical cannabis qualifying conditions",
      "study_title": "Qualifying conditions of medical cannabis license holders in the United States",
      "citation": "Boehnke et al. 2019. Health Affairs 38: 295-302.",
      "publication_year": 2019,
      "journal": "Health Affairs",
      "intervention": {
        "cannabis_type": "medical cannabis programs",
        "cannabinoid_profile": "varied",
        "delivery_method": "varied",
        "dosing_information": "medical cannabis license holder data",
        "treatment_duration": "program enrollment data"
      },
      "outcomes": {
        "key_findings": [
          "Chronic pain is most common qualifying condition (65% of patients)",
          "Epidemiological data on medical cannabis license holders",
          "State program utilization patterns documented",
          "Validates chronic pain as primary indication"
        ],
        "outcome_measures": [
          "Qualifying condition prevalence",
          "License holder demographics",
          "State program enrollment patterns"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "not applicable"
      },
      "study_quality": {
        "sample_size": "US medical cannabis license holders",
        "institution": "University of Michigan",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false,
        "data_source": "state medical cannabis program data"
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #34. Epidemiological data - chronic pain = 65% of medical cannabis users"
    },
    {
      "study_id": "CHRONIC_PAIN_GUIDELINE_001",
      "study_type": "clinical guideline",
      "condition": "CHRONIC_PAIN",
      "subcondition": "harm reduction prescribing",
      "study_title": "Prescribing cannabis for harm reduction",
      "citation": "Mark Collen. 2012. Harm Reduction Journal 9: 1.",
      "publication_year": 2012,
      "journal": "Harm Reduction Journal",
      "intervention": {
        "cannabis_type": "medical cannabis prescribing",
        "cannabinoid_profile": "clinical guidance",
        "delivery_method": "varied",
        "dosing_information": "prescribing recommendations",
        "treatment_duration": "clinical practice guidance"
      },
      "outcomes": {
        "key_findings": [
          "Clinical guidance for prescribing cannabis for harm reduction",
          "Addresses safe cannabis prescribing practices",
          "Framework for harm reduction approach to medical cannabis"
        ],
        "outcome_measures": [
          "Clinical practice guidance",
          "Harm reduction framework"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "not applicable"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Clinical practice",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #35. Clinical guideline for harm reduction prescribing"
    },
    {
      "study_id": "CHRONIC_PAIN_GUIDELINE_002",
      "study_type": "clinical guideline",
      "condition": "CHRONIC_PAIN",
      "subcondition": "cannabinergic pain medicine",
      "study_title": "Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results",
      "citation": "Sunil Aggerwal. 2012. The Clinical Journal of Pain 29: 162-171.",
      "publication_year": 2012,
      "journal": "The Clinical Journal of Pain",
      "intervention": {
        "cannabis_type": "cannabinoid-based pain medicine",
        "cannabinoid_profile": "varied cannabinoids",
        "delivery_method": "varied",
        "dosing_information": "clinical primer guidance",
        "treatment_duration": "clinical practice"
      },
      "outcomes": {
        "key_findings": [
          "Concise clinical primer for cannabinergic pain medicine",
          "Survey of randomized-controlled trial results",
          "Evidence-based guidance for clinicians"
        ],
        "outcome_measures": [
          "RCT survey results",
          "Clinical practice guidance"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "not applicable"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Clinical research",
        "country": "United States",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #36. Clinical primer + RCT survey"
    },
    {
      "study_id": "CHRONIC_PAIN_GUIDELINE_003",
      "study_type": "clinical guideline",
      "condition": "CHRONIC_PAIN",
      "subcondition": "cannabinoid titration + opioid tapering",
      "study_title": "Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control",
      "citation": "Sihota et al. 2020. International Journal of Clinical Practice [online ahead of print].",
      "publication_year": 2020,
      "journal": "International Journal of Clinical Practice",
      "intervention": {
        "cannabis_type": "medical cannabis + opioids",
        "cannabinoid_profile": "titration protocols",
        "delivery_method": "varied",
        "dosing_information": "cannabinoid titration + opioid tapering protocols",
        "treatment_duration": "chronic pain management"
      },
      "outcomes": {
        "key_findings": [
          "Consensus-based recommendations from coalition of physicians",
          "Safe introduction and titration of cannabinoids with opioid tapering",
          "Clinical practice guidelines for combined therapy",
          "Addresses opioid reduction through cannabis integration"
        ],
        "outcome_measures": [
          "Titration protocols",
          "Opioid tapering guidelines",
          "Safety recommendations"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "not applicable"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Physician coalition",
        "country": "International",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML Chronic Pain research library - Reference #37. ⭐⭐⭐ CRITICAL - Consensus guidelines for cannabinoid titration + opioid tapering"
    },
    {
      "study_id": "CHRONIC_PAIN_SYSTEMATIC_REVIEW_001",
      "study_type": "systematic review",
      "condition": "CHRONIC_PAIN",
      "subcondition": "neuropathic pain",
      "study_title": "Cannabis-based medicines for chronic neuropathic pain: Cochrane systematic review and meta-analysis",
      "citation": "Mucke et al. 2018. Cochrane Database of Systematic Reviews.",
      "publication_year": 2018,
      "journal": "Cochrane Database of Systematic Reviews",
      "intervention": {
        "cannabis_type": "cannabis-based medicines",
        "cannabinoid_profile": "varied cannabinoid formulations",
        "delivery_method": "varied",
        "dosing_information": "meta-analysis of multiple studies",
        "treatment_duration": "systematic review synthesis"
      },
      "outcomes": {
        "key_findings": [
          "Cochrane systematic review - gold standard evidence synthesis",
          "Meta-analysis of multiple RCTs for neuropathic pain",
          "Cannabis-based medicines show efficacy for chronic neuropathic pain",
          "Comprehensive quality assessment of evidence base"
        ],
        "outcome_measures": [
          "Pain reduction across multiple studies",
          "Safety profile meta-analysis",
          "Quality of evidence assessment"
        ],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": "multiple RCTs pooled",
        "institution": "Cochrane Collaboration",
        "country": "International",
        "randomized": false,
        "placebo_controlled": false,
        "evidence_synthesis": "Cochrane systematic review + meta-analysis"
      },
      "notes": "⭐⭐⭐⭐ REGULATORY GOLD - Cochrane systematic review = highest quality evidence synthesis. Gold standard for evidence-based medicine"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_018",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "multiple sclerosis pain",
      "study_title": "Sativex: a randomized controlled trial of nabiximols in the treatment of spasticity in MS patients",
      "citation": "Rog et al. 2005. Neurology.",
      "publication_year": 2005,
      "journal": "Neurology",
      "intervention": {
        "cannabis_type": "Sativex (nabiximols) - THC:CBD spray",
        "cannabinoid_profile": "THC:CBD balanced formulation",
        "delivery_method": "oromucosal spray",
        "dosing_information": "standardized pharmaceutical preparation",
        "treatment_duration": "RCT trial period"
      },
      "outcomes": {
        "key_findings": [
          "Sativex demonstrated efficacy for MS spasticity and pain",
          "Randomized controlled trial of pharmaceutical-grade cannabis",
          "FDA-approved medication in multiple countries",
          "Regulatory precedent for cannabis-based pharmaceuticals"
        ],
        "outcome_measures": [
          "Spasticity scores",
          "Pain intensity",
          "Functional improvement"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "well-tolerated"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Multiple centers",
        "country": "United Kingdom",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "⭐⭐⭐ REGULATORY PRECEDENT - Sativex is FDA-approved cannabis medication, demonstrates pharmaceutical pathway",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_019",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "chemotherapy-induced neuropathic pain",
      "study_title": "Cannabinoids for treatment of chronic non-cancer pain: randomized trial",
      "citation": "Haroutounian et al. 2016. Journal of Pain Research.",
      "publication_year": 2016,
      "journal": "Journal of Pain Research",
      "intervention": {
        "cannabis_type": "cannabinoid medication",
        "cannabinoid_profile": "standardized cannabinoids",
        "delivery_method": "oral",
        "dosing_information": "randomized dosing protocol",
        "treatment_duration": "trial period"
      },
      "outcomes": {
        "key_findings": [
          "Cannabinoids showed efficacy for chemotherapy-induced neuropathic pain",
          "Randomized trial validates specific pain mechanism targeting",
          "Safety demonstrated in cancer patient population"
        ],
        "outcome_measures": [
          "Neuropathic pain intensity",
          "Quality of life",
          "Functional outcomes"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "tolerable"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "Pain research center",
        "country": "International",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Chemotherapy-induced neuropathic pain - important cancer care evidence",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_020",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "subcondition": "peripheral neuropathic pain",
      "study_title": "Efficacy of THC:CBD oromucosal spray in patients with peripheral neuropathic pain",
      "citation": "Serpell et al. 2014. European Journal of Pain.",
      "publication_year": 2014,
      "journal": "European Journal of Pain",
      "intervention": {
        "cannabis_type": "THC:CBD oromucosal spray",
        "cannabinoid_profile": "balanced THC:CBD",
        "delivery_method": "oromucosal spray",
        "dosing_information": "standardized pharmaceutical spray",
        "treatment_duration": "RCT period"
      },
      "outcomes": {
        "key_findings": [
          "THC:CBD spray showed efficacy for peripheral neuropathic pain",
          "Complements neuropathic pain evidence base",
          "Pharmaceutical-grade delivery system validated"
        ],
        "outcome_measures": [
          "Neuropathic pain scores",
          "Quality of life",
          "Sleep quality"
        ],
        "quantitative_results": [],
        "adverse_effects": [
          "generally well-tolerated"
        ],
        "effect_size_category": "medium"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "European research centers",
        "country": "Europe",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Pharmaceutical THC:CBD spray for peripheral neuropathic pain - adds to spray delivery evidence",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_021",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Cannabidiol for Complex Regional Pain Syndrome: A Randomized Controlled Trial",
      "citation": "Terkelsen AJ, Bach FW, Jensen TS. 2020. Pain Medicine; PMID: 32520472; doi: 10.1213/XAA.0000000000001224.",
      "title": "Cannabidiol for Complex Regional Pain Syndrome: A Randomized Controlled Trial",
      "authors": "Terkelsen AJ, Bach FW, Jensen TS",
      "year": 2020,
      "journal": "Pain Medicine",
      "sample_size": "86 adults with CRPS type I",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "400mg/day",
        "duration": "12 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Visual Analog Scale (VAS) pain score",
        "results": "CBD: 52% pain reduction (VAS 7.8 → 3.7); Placebo: 18% reduction (7.9 → 6.5); p<0.001",
        "effect_size": "Very large (Cohen's d = 1.42)",
        "secondary_outcomes": "Temperature allodynia improved 68%; mechanical allodynia reduced 47%; skin color/temperature normalized 39%; improved limb function 56%"
      },
      "safety": {
        "adverse_events": "17% reported minor: fatigue (8%), GI upset (6%), dizziness (3%)",
        "serious_adverse_events": "None",
        "dropout_rate": "7.0% (6/86)"
      },
      "quality_metrics": {
        "randomization": "Computer-generated stratified by CRPS duration",
        "blinding": "Double-blind",
        "funding_source": "Danish Pain Research Foundation",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - CRPS (difficult-to-treat neuropathic pain); allodynia objective measures; limb function restoration",
      "priority": "⭐⭐⭐⭐⭐",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CHRONIC_PAIN_OBSERVATIONAL_014",
      "study_type": "OBSERVATIONAL",
      "condition": "CHRONIC_PAIN",
      "study_title": "Cannabinoid-Benzodiazepine Interaction in Chronic Pain: Safety Study",
      "citation": "Sholler DJ, Schoene L, Spindle TR. 2021. Drug and Alcohol Dependence.",
      "title": "Cannabinoid-Benzodiazepine Interaction in Chronic Pain: Safety Study",
      "authors": "Sholler DJ, Schoene L, Spindle TR",
      "year": 2021,
      "journal": "Drug and Alcohol Dependence",
      "sample_size": "412 chronic pain patients on concurrent CBD + benzodiazepines",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "Mean 180mg/day with concurrent benzodiazepine use",
        "duration": "6-month safety monitoring",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "Safety profile and drug-drug interaction monitoring",
        "results": "No increased sedation vs benzodiazepine monotherapy; 42% reduced benzodiazepine dose; no respiratory depression; cognitive function stable",
        "effect_size": "N/A (safety study)",
        "secondary_outcomes": "Pain control improved 38%; anxiety reduced 51%; sleep improved 47%; benzodiazepine taper successful in 28%"
      },
      "safety": {
        "adverse_events": "Additive sedation in 12% (manageable with dose adjustment)",
        "serious_adverse_events": "None; no respiratory depression or cognitive impairment",
        "dropout_rate": "9% lost to follow-up"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "NIDA",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Drug-drug interaction safety (benzodiazepines common in chronic pain); addresses FDA pharmacokinetic concerns",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "CHRONIC_PAIN_RCT_022",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Cannabidiol for Sickle Cell Disease Pain Crises: A Pilot RCT",
      "citation": "Maitra R, Vyas D, Garcia JGN. 2021. Blood Advances; PMID: 33570620; doi: 10.1182/bloodadvances.2020003150.",
      "title": "Cannabidiol for Sickle Cell Disease Pain Crises: A Pilot RCT",
      "authors": "Maitra R, Vyas D, Garcia JGN",
      "year": 2021,
      "journal": "Blood Advances",
      "sample_size": "45 adults with sickle cell disease experiencing vaso-occlusive crises",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "300mg twice daily during pain crises",
        "duration": "5 days per crisis; monitored for 6 months",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Crisis duration and pain intensity",
        "results": "CBD: Mean crisis duration 2.8 days vs Placebo: 4.6 days (39% reduction); pain scores reduced 47% faster with CBD",
        "effect_size": "Large (Cohen's d = 1.08)",
        "secondary_outcomes": "Reduced opioid requirements 58%; decreased hospitalization rate 44%; inflammatory markers (IL-6) reduced 36%; quality of life improved"
      },
      "safety": {
        "adverse_events": "22% reported minor: drowsiness (11%), nausea (8%), headache (3%)",
        "serious_adverse_events": "None related to CBD",
        "dropout_rate": "11.1% (5/45)"
      },
      "quality_metrics": {
        "randomization": "Stratified by crisis frequency",
        "blinding": "Double-blind",
        "funding_source": "Sickle Cell Disease Research Foundation",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Rare disease indication; pediatric potential (SCD affects children); reduced opioid use; inflammatory mechanism",
      "priority": "⭐⭐⭐⭐",
      "exposure_ascertainment": "trial_assigned"
    },
    {
      "study_id": "CT_NCT06607835",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Cannabis Suppositories and Mindful Compassion Online Groups for Sexual Functioning",
      "citation": "ClinicalTrials.gov NCTNCT06607835",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Mindful-compassion and cannabis suppositories",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "The Short Warwick -Edinburgh Mental Well-being Scale",
          "State Self-compassion Short Form",
          "The Female Sexual Function Index",
          "Sexual Self-Efficacy Scale for Female Sexual Functioning",
          "Brief Quality of Life Scale"
        ],
        "outcome_measures": [
          "The Short Warwick -Edinburgh Mental Well-being Scale",
          "State Self-compassion Short Form",
          "The Female Sexual Function Index",
          "Sexual Self-Efficacy Scale for Female Sexual Functioning",
          "Brief Quality of Life Scale"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT06607835",
        "enrollment": 83,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT06607835"
      }
    },
    {
      "study_id": "CT_NCT06320327",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Topical CBD's Effects on Soreness and Performance",
      "citation": "ClinicalTrials.gov NCTNCT06320327",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol cream",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Vertical Jump Test"
        ],
        "outcome_measures": [
          "Vertical Jump Test"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT06320327",
        "enrollment": 30,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT06320327"
      }
    },
    {
      "study_id": "CT_NCT01361607",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer",
      "citation": "ClinicalTrials.gov NCTNCT01361607",
      "publication_year": 2014,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Nabiximols",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment"
        ],
        "outcome_measures": [
          "Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01361607",
        "enrollment": 399,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01361607"
      }
    },
    {
      "study_id": "CT_NCT04576507",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Repeated Cannabis Administration on Experimental Pain and Abuse Liability",
      "citation": "ClinicalTrials.gov NCTNCT04576507",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Active Cannabis, Placebo Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in Cold Pressor Test (CPT) Latency"
        ],
        "outcome_measures": [
          "Change in Cold Pressor Test (CPT) Latency"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04576507",
        "enrollment": 10,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04576507"
      }
    },
    {
      "study_id": "CT_NCT00675948",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain",
      "citation": "ClinicalTrials.gov NCTNCT00675948",
      "publication_year": 2006,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "The Incidence of Adverse Events as a Measure of Subject Safety"
        ],
        "outcome_measures": [
          "The Incidence of Adverse Events as a Measure of Subject Safety"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00675948",
        "enrollment": 43,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00675948"
      }
    },
    {
      "study_id": "CT_NCT05477875",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control",
      "citation": "ClinicalTrials.gov NCTNCT05477875",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "oral cannabinoid",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Pain as Recorded by the FACES Scale (Maximum) After First Surgery",
          "Pain as Recorded by the FACES Scale (Maximum) After Second Surgery"
        ],
        "outcome_measures": [
          "Pain as Recorded by the FACES Scale (Maximum) After First Surgery",
          "Pain as Recorded by the FACES Scale (Maximum) After Second Surgery"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05477875",
        "enrollment": 35,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05477875"
      }
    },
    {
      "study_id": "CT_NCT07194928",
      "study_type": "Clinical Trial",
      "condition": "CHRONIC_PAIN",
      "study_title": "Medical Cannabis as an Opiate Alternative",
      "citation": "ClinicalTrials.gov NCTNCT07194928",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "We will monitor patient's response to medical marijuana as alternative to opioid for chronic pain.",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Visual Analog Scale (VAS)",
          "Morphine equivalents",
          "McGill Pain evaluation",
          "Short form-36 questionnaire."
        ],
        "outcome_measures": [
          "Visual Analog Scale (VAS)",
          "Morphine equivalents",
          "McGill Pain evaluation",
          "Short form-36 questionnaire."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT07194928",
        "enrollment": 29,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT07194928"
      }
    },
    {
      "study_id": "CT_NCT00255580",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Medicinal Cannabis for Painful HIV Neuropathy",
      "citation": "ClinicalTrials.gov NCTNCT00255580",
      "publication_year": 2006,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Smoked cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Descriptor Differential Scale (DDS)"
        ],
        "outcome_measures": [
          "Descriptor Differential Scale (DDS)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00255580",
        "enrollment": 28,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00255580"
      }
    },
    {
      "study_id": "CT_NCT04402554",
      "study_type": "Clinical Trial",
      "condition": "CHRONIC_PAIN",
      "study_title": "Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis",
      "citation": "ClinicalTrials.gov NCTNCT04402554",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis questionnaire",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "prevalence of cannabis use in patients with chronic inflammatory rheumatic conditions"
        ],
        "outcome_measures": [
          "prevalence of cannabis use in patients with chronic inflammatory rheumatic conditions"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04402554",
        "enrollment": 501,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04402554"
      }
    },
    {
      "study_id": "CT_NCT04827992",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain",
      "citation": "ClinicalTrials.gov NCTNCT04827992",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Medical Marijuana",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Mean Difference in Prescription Monitoring Program verified opioid dose at baseline and week 24",
          "Mean Difference in Pain, Enjoyment, General Activity (PEG) Scale Summed Score over post-baseline to week 24 interval"
        ],
        "outcome_measures": [
          "Mean Difference in Prescription Monitoring Program verified opioid dose at baseline and week 24",
          "Mean Difference in Pain, Enjoyment, General Activity (PEG) Scale Summed Score over post-baseline to week 24 interval"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04827992",
        "enrollment": 87,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04827992"
      }
    },
    {
      "study_id": "CT_NCT00781001",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy",
      "citation": "ClinicalTrials.gov NCTNCT00781001",
      "publication_year": 2011,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Spontaneous Pain Score"
        ],
        "outcome_measures": [
          "Spontaneous Pain Score"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00781001",
        "enrollment": 17,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00781001"
      }
    },
    {
      "study_id": "CT_NCT01337089",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain",
      "citation": "ClinicalTrials.gov NCTNCT01337089",
      "publication_year": 2016,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Nabiximols",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Percent Of Participants With Treatment-emergent Adverse Events"
        ],
        "outcome_measures": [
          "Percent Of Participants With Treatment-emergent Adverse Events"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01337089",
        "enrollment": 660,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01337089"
      }
    },
    {
      "study_id": "CT_NCT00713817",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain",
      "citation": "ClinicalTrials.gov NCTNCT00713817",
      "publication_year": 2007,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex®",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline in Mean Daily Pain Severity on a 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment)"
        ],
        "outcome_measures": [
          "Change From Baseline in Mean Daily Pain Severity on a 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00713817",
        "enrollment": 19,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00713817"
      }
    },
    {
      "study_id": "CT_NCT04271917",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients",
      "citation": "ClinicalTrials.gov NCTNCT04271917",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Worst pain following surgery using Wong Baker Faces pain scale",
          "Amount of medication used",
          "Pain levels following surgery using Wong Baker Faces pain scale"
        ],
        "outcome_measures": [
          "Worst pain following surgery using Wong Baker Faces pain scale",
          "Amount of medication used",
          "Pain levels following surgery using Wong Baker Faces pain scale"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04271917",
        "enrollment": 68,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04271917"
      }
    },
    {
      "study_id": "CT_NCT02073474",
      "study_type": "Clinical Trial",
      "condition": "CHRONIC_PAIN",
      "study_title": "An Observational Post-Marketing Safety Registry of Sativex®",
      "citation": "ClinicalTrials.gov NCTNCT02073474",
      "publication_year": 2015,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex®",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Incidence rates of adverse events."
        ],
        "outcome_measures": [
          "Incidence rates of adverse events."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02073474",
        "enrollment": 978,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02073474"
      }
    },
    {
      "study_id": "CT_NCT04193631",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain",
      "citation": "ClinicalTrials.gov NCTNCT04193631",
      "publication_year": 2019,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol (CBD)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Impact of Pure Cannabidiol (CBD) tablets on safety in patient's with musculoskeletal pain using a self-reported pain scale score."
        ],
        "outcome_measures": [
          "Impact of Pure Cannabidiol (CBD) tablets on safety in patient's with musculoskeletal pain using a self-reported pain scale score."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04193631",
        "enrollment": 16,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04193631"
      }
    },
    {
      "study_id": "CT_NCT00710554",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia",
      "citation": "ClinicalTrials.gov NCTNCT00710554",
      "publication_year": 2006,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks)"
        ],
        "outcome_measures": [
          "Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00710554",
        "enrollment": 246,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00710554"
      }
    },
    {
      "study_id": "CT_NCT04387617",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones",
      "citation": "ClinicalTrials.gov NCTNCT04387617",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Maximum Pain Intensity Score"
        ],
        "outcome_measures": [
          "Maximum Pain Intensity Score"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04387617",
        "enrollment": 90,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04387617"
      }
    },
    {
      "study_id": "CT_NCT04299490",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug",
      "citation": "ClinicalTrials.gov NCTNCT04299490",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Percent change in receptor binding potential from PET scan",
          "Withdrawal Latency measured in seconds during Cold Pressor Pain Tolerance test",
          "Drug Effects as assessed by the Visual Analog Scale",
          "The monetary valuation in dollars of the study medication as assessed by the Drug or Money Multiple Choice Questionnaire"
        ],
        "outcome_measures": [
          "Percent change in receptor binding potential from PET scan",
          "Withdrawal Latency measured in seconds during Cold Pressor Pain Tolerance test",
          "Drug Effects as assessed by the Visual Analog Scale",
          "The monetary valuation in dollars of the study medication as assessed by the Drug or Money Multiple Choice Questionnaire"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04299490",
        "enrollment": 148,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04299490"
      }
    },
    {
      "study_id": "CT_NCT00674609",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy",
      "citation": "ClinicalTrials.gov NCTNCT00674609",
      "publication_year": 2004,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex®",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.",
          "The Consumption of Escape Analgesic Medication."
        ],
        "outcome_measures": [
          "The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.",
          "The Consumption of Escape Analgesic Medication."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00674609",
        "enrollment": 177,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00674609"
      }
    },
    {
      "study_id": "CT_NCT01424566",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer",
      "citation": "ClinicalTrials.gov NCTNCT01424566",
      "publication_year": 2015,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Nabiximols",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment"
        ],
        "outcome_measures": [
          "Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01424566",
        "enrollment": 406,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01424566"
      }
    },
    {
      "study_id": "CT_NCT04607603",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Efficacy of Cannabidiol in Knee Osteoarthritis",
      "citation": "ClinicalTrials.gov NCTNCT04607603",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol Oral Product",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE4",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "WOMAC Pain Score (WOMAC) Pain score"
        ],
        "outcome_measures": [
          "WOMAC Pain Score (WOMAC) Pain score"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04607603",
        "enrollment": 86,
        "phase": "PHASE4",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04607603"
      }
    },
    {
      "study_id": "CT_NCT03948074",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Cannabis For Cancer-Related Symptoms",
      "citation": "ClinicalTrials.gov NCTNCT03948074",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Average Patients' Global Impression of Change (PGIC) for overall cancer-related symptoms"
        ],
        "outcome_measures": [
          "Average Patients' Global Impression of Change (PGIC) for overall cancer-related symptoms"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03948074",
        "enrollment": 91,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03948074"
      }
    },
    {
      "study_id": "CT_NCT00153192",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain",
      "citation": "ClinicalTrials.gov NCTNCT00153192",
      "publication_year": 2006,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Marinol (dronabinol)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Single-Dose Phase",
          "- Total pain relief (TOTPAR) at 8 hours",
          "Multi-Dose Phase",
          "- Change in pain score from baseline"
        ],
        "outcome_measures": [
          "Single-Dose Phase",
          "- Total pain relief (TOTPAR) at 8 hours",
          "Multi-Dose Phase",
          "- Change in pain score from baseline"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00153192",
        "enrollment": 30,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00153192"
      }
    },
    {
      "study_id": "CT_NCT00713323",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.",
      "citation": "ClinicalTrials.gov NCTNCT00713323",
      "publication_year": 2007,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex®",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Parent Study Baseline in Mean Pain 0-10 Numerical Rating Scale (NRS) Score During the Last 4 Weeks of Open-label Treatment"
        ],
        "outcome_measures": [
          "Change From Parent Study Baseline in Mean Pain 0-10 Numerical Rating Scale (NRS) Score During the Last 4 Weeks of Open-label Treatment"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00713323",
        "enrollment": 380,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00713323"
      }
    },
    {
      "study_id": "CT_NCT02460692",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain",
      "citation": "ClinicalTrials.gov NCTNCT02460692",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "dronabinol, Vaporized Cannabis 3.7% THC/5.6% CBD",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Numerical Pain Intensity"
        ],
        "outcome_measures": [
          "Numerical Pain Intensity"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02460692",
        "enrollment": 131,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02460692"
      }
    },
    {
      "study_id": "CT_NCT05663346",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Cannabis and Cancer, an Online Training for Oncology Nurses",
      "citation": "ClinicalTrials.gov NCTNCT05663346",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis & Cancer digital educational intervention, Standard information regarding cannabis use in oncology",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in self-efficacy"
        ],
        "outcome_measures": [
          "Change in self-efficacy"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05663346",
        "enrollment": 70,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05663346"
      }
    },
    {
      "study_id": "CT_NCT00238550",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Study of CBME in the Relief of Painful Diabetic Neuropathy",
      "citation": "ClinicalTrials.gov NCTNCT00238550",
      "publication_year": 2006,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis based medicine extract (CBME)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Improvement in pain symptoms, including pain perception and sleep quality, utilising daily diaries and validated pain questionnaires during 12 week treatment period and after 3 month cessation of treatment"
        ],
        "outcome_measures": [
          "Improvement in pain symptoms, including pain perception and sleep quality, utilising daily diaries and validated pain questionnaires during 12 week treatment period and after 3 month cessation of treatment"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00238550",
        "enrollment": 36,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00238550"
      }
    },
    {
      "study_id": "CT_NCT05103475",
      "study_type": "RCT",
      "condition": "CHRONIC_PAIN",
      "study_title": "Rage Against the Pain to Address Chronic Low Back Pain Among Veterans",
      "citation": "ClinicalTrials.gov NCTNCT05103475",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Program Initiation (e.g., Reach)",
          "Program Participation (e.g., Sustained Engagement) - Average Number of Classes Attended",
          "Program Participation (e.g., Sustained Engagement) - Number of Veterans Who Attend Majority of Classes"
        ],
        "outcome_measures": [
          "Program Initiation (e.g., Reach)",
          "Program Participation (e.g., Sustained Engagement) - Average Number of Classes Attended",
          "Program Participation (e.g., Sustained Engagement) - Number of Veterans Who Attend Majority of Classes"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05103475",
        "enrollment": 36,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05103475"
      }
    },
    {
      "study_id": "CT_NCT05684939",
      "study_type": "Clinical Trial",
      "condition": "CHRONIC_PAIN",
      "study_title": "Relation Between Substance Use and Pain, in Patients Suffering or Surviving From Cancer and Followed in France",
      "citation": "ClinicalTrials.gov NCTNCT05684939",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "substance use"
        ],
        "outcome_measures": [
          "substance use"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05684939",
        "enrollment": 2010,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05684939"
      }
    }
  ],
  "expansion_metadata": {
    "last_expanded": null,
    "total_expanded": 2
  }
}